Clinical Trials Sponsored by Pierre Fabre Dermatology

Total 151 results

Pierre Fabre Medicament

Withdrawn

Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis (VESTA)

Knee Osteoarthritis
Pierre Fabre Medicament

Completed

Brain Imaging Study of F17464

Healthy Volunteers

United States
Pierre Fabre Medicament

Completed

Nicotine Patch Safety Study

Smokers

France
Pierre Fabre Medicament

Completed

Acute Sore Throat Pain Study

Acute Sore Throat Pain

United Kingdom, France, Germany
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment (BERING-CRC)

Metastatic Colorectal Carcinoma

Austria, Germany
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Active, not recruiting

Real-life Pan-HER-blockade With Neratinib (ELEANOR)

Breast Neoplasm

Austria, Germany, Switzerland
UNICANCER
Pierre Fabre Medicament

Recruiting

A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer (COBRAF)

Metastatic Colorectal Cancer | BRAF V600E Mutation Positive

France
Pierre Fabre Dermo Cosmetique

Completed

Clinical and Biological Anti-aging Efficacy of a Cosmetic Cream

Anti-aging

France
Pierre Fabre Dermo Cosmetique

Completed

Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects

Acne

France
Pierre Fabre Dermo Cosmetique

Terminated

Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD

Dermatitis, Atopic

France
Pierre Fabre Dermo Cosmetique

Completed

Assess the Effects and the Tolerance of Cosmetic Product in the Follow-up Phase of Facial Acne for 1 Year

Acne Vulgaris

France, Italy, Poland
Pierre Fabre Dermo Cosmetique

Completed

Assessment of the Wound Healing Efficacy and Tolerance of a Medical Device on Wounds in Healthy Subjects.

Healthy

Germany
Pierre Fabre Dermo Cosmetique

Completed

Efficacy Study of Cosmetic Product Against Telogen Effluvium on Women

Telogen Effluvium

France
Pierre Fabre Dermo Cosmetique

Completed

Demonstration of the Presence of a Carbonyl Stress in the Hair Follicles of Postpartum Women

Telogen Effluvium

France
Pierre Fabre Dermo Cosmetique

Withdrawn

Identification of Biomarkers and Characterization of Melasma

Chloasma
Pierre Fabre Medicament
ClinSearch

Withdrawn

Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand Eczema (CARING)

Chronic Hand Eczema
Pierre Fabre Pharma AG

Completed

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). (Real-CHOICE)

Iron-Deficiency Anemia | Iron-Deficiency

Switzerland
Pfizer
Pierre Fabre Laboratories

Active, not recruiting

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Melanoma

United States, Spain, Belgium, Canada, Netherlands
Pierre Fabre Medicament
Clinact

Completed

A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) (CAPSTAN CRC)

Metastatic Colorectal Cancer | BRAF V600E Mutation Positive

France, United Kingdom, Spain, Belgium, Germany, Italy, Austria
Pierre Fabre Dermo Cosmetique

Completed

Efficacy Study of Cosmetic Product on Xerosis Induced by Systemic Anticancer Treatments

Xerosis

France
Pierre Fabre Dermo Cosmetique

Completed

IN-USE TOLERANCE STUDY UNDER DERMATOLOGICAL AND OPHTHALMOLOGICAL CONTROLS AND EFFICACY ASSESSMENT (Face Cream)

Hypersensitive | Reactive and Intolerant Skin | Redness-prone Skin | Stinger Subjects

China
Pierre Fabre Medicament
Biotrial

Active, not recruiting

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
Pierre Fabre Dermo Cosmetique

Completed

Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin

Acne

France
Pierre Fabre Dermo Cosmetique

Completed

An Exploratory Study to Assess the Efficacy of the Avène Hydrotherapy (PAP)

Chronic Pruritus Due to Plaque Psoriasis

Spain, France
Pierre Fabre Dermo Cosmetique

Completed

Demonstration of Carbonyl Stress on Hair Follicles

Effluvium; Telogen

France
Pierre Fabre Dermo Cosmetique

Completed

Avene Compact Honey for Prevention of Pigmentation From Visible Light

Healthy

Canada
Pierre Fabre Dermo Cosmetique

Not yet recruiting

Evaluation of the Tolerance of the Medical Device RL3010A - DP0378 in Children and Adults Presenting a Superficial Wound After a Dermatological Procedure

Skin Abrasion | Superficial Wound
Pierre Fabre Dermo Cosmetique

Not yet recruiting

Evaluate the Efficacy and the Tolerance of the Medical Device V063B-DP3003 on Dentin Hypersensitivity During Teeth Whitening

Tooth Whitening
Pierre Fabre Dermo Cosmetique

Completed

Re-epithelialization Efficacy Evaluation of Cosmetic Product RV1551P vs Non-treated Forearm of Healthy Adult Women

Healthy

France
Pierre Fabre Dermo Cosmetique

Completed

Photoprotective Effects of a SPF50+ Sunscreen on Skin Genotoxicity Induced by Repeated Chronic Outdoor Sun Exposure

Sun Damaged Skin

France
Pierre Fabre Dermo Cosmetique

Completed

Determination of Product Thickness Applied on Different Areas of the Face Using a Multispectral Imaging Method

Sunscreen

France
Pierre Fabre Medicament
Biotrial

Completed

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
Pfizer
Pierre Fabre Laboratories

Terminated

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Melanoma

Italy
Pierre Fabre Medicament
Clinact

Completed

Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial

Actinic Keratoses

France, Germany, Italy, Spain
Pierre Fabre Dermo Cosmetique

Completed

IN-USE TOLERANCE STUDY UNDER DERMATOLOGICAL AND OPHTHALMOLOGICAL CONTROLS AND EFFICACY ASSESSMENT (Face Balm)

Hypersensitive | Reactive and Intolerant Skin | Redness-prone Skin | Stinger Subjects

China
Pierre Fabre Dermo Cosmetique

Completed

Sunscreen Efficacy Against the Reccurence of Lesions Post-sun Exposure in Acneic Subjects

Acne

Portugal
Pierre Fabre Dermo Cosmetique

Unknown

Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis

Healthy | Rosacea | Seborrheic Dermatitis | Atopic Dermatitis | Psoriasis Vulgaris | Acne

France
Pierre Fabre Dermo Cosmetique

Completed

Collection of Clinical and Instrumental Data in Adult Subjects Suffering From Atopic Dermatitis

Atopic Dermatitis

France
Pierre Fabre Dermo Cosmetique

Completed

Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy

Hyperpigmentation | Lentigo
Pierre Fabre Dermo Cosmetique

Unknown

Oral and Dental Tolerance and Efficacy on Dentinal Hypersensitivity of a Dental Gel, on Adults

Dentinal Hypersensitivity

United Kingdom
Pierre Fabre Dermo Cosmetique

Unknown

Efficacy and Safety of RV4104A Ointment in Onychomycosis

Onychomycosis

France
ARCAGY/ GINECO GROUP
Pierre Fabre Laboratories

Terminated

Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer. (CHEOPS)

Breast Cancer

France
University of Aarhus
Pierre Fabre Laboratories

Completed

Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer (XeNa)

Breast Cancer

Denmark
University of Lausanne
Pierre Fabre Laboratories

Completed

Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors (ferdon)

Fatigue | Iron Deficiency

Switzerland
Pierre Fabre Pharma GmbH
iOMEDICO AG

Completed

Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer | Non Small Cell Lung Carcinoma

Germany
Pierre Fabre Medicament
Bristol-Myers Squibb

Completed

Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract

Bladder Cancer | Bladder Neoplasms | Transitional Cell Carcinoma of the Urothelial Tract

Canada
Pierre Fabre Dermo Cosmetique
Quanta Medical

Unknown

Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis (ONICO)

Onychomycosis

France
Pierre Fabre Medicament
Iqvia Pty Ltd

Recruiting

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib (NEAR)

Breast Cancer | HER2-positive Breast Cancer | Adjuvant Therapy

Belgium
University Hospital, Limoges
Pierre Fabre Laboratories

Completed

Concomitant Radio-chemotherapy in the Elderly (RACCOSA)

Non Small Cell Lung Cancer

France
Bristol-Myers Squibb
Pierre Fabre Medicament

Completed

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Kidney Neoplasms | Transitional Cell Carcinoma | Bladder Cancer | Bladder Neoplasms | Ureter Neoplasms | Neoplasm, Bladder

United States, Spain, Italy, Canada, Indonesia, Singapore, Australia, Austria, France, Greece, Korea, Republic of, Philippines, Sweden, Switzerland, Thailand

3

Subscribe